A randomized, double-blind, placebo-controlled Phase 2 trial of avelumab in combination with EP-101 STEMVAC in women with breast cancer

Trial Profile

A randomized, double-blind, placebo-controlled Phase 2 trial of avelumab in combination with EP-101 STEMVAC in women with breast cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Avelumab (Primary) ; EP 101-EpiThany (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2017 New trial record
    • 10 May 2017 This trial is expected to begin in the first quarter of 2018, according to an EpiThany media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top